Key Clinical Points Essential Thrombocythemia Essential thrombocythemia is associated
with an increased risk of thrombosis and bleeding. Most patients with essential …

Abstract Objective To document the Mayo Clinic decades-long experience with
myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and …

Primary myelofibrosis is a chronic clonal stem cell disorder that results in a build-up of
marrow fibrosis and dysfunction, hypermetabolic states, and myeloid metaplasia. The …

The aim of this study is to compare clinical outcomes of patients who underwent allogeneic
stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) …

Introduction Myelofibrosis (MF) is a disease of elderly with median age of 65 years at
diagnosis. Allogeneic stem cell transplantation (ASCT) currently is the only potentially …

Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of
hematological presentations, including thrombosis, bleeding diathesis and marrow fibrosis …

Introduction: Despite our recent progress in the understanding of essential thrombocythemia
(ET) pathogenesis, the therapeutic management of this disease has remained largely …

Management of essential thrombocythemia (ET) starts with confirming the accuracy of the
diagnosis and excluding congenital and reactive thrombocytosis and myeloid neoplasms …

Background: Myeloproliferative neoplasm (MPN) are group of malignant hematologic
diseases related to abnormal hematopoietic stem cell, including chronic myeloid leukemia …

Background: Thiol-disulphide homeostasis has vital role in cell signalling mechanisms,
regulation of transcription factors and enzymatic activities, signal transduction and regulation …